Coronavirus vaccine candidate shows promise in early trial, Moderna says


Moderna has revealed some promising findings on its coronavirus vaccine candidate.
The company said Monday that during the phase one trial of its potential COVID-19 vaccine it has been developing, eight patients developed antibodies at levels that were on par with those who recovered from the virus, Stat News reports.
Moderna described the interim data from this trial as "positive," with Chief Medical Officer Tal Zaks saying that the findings, though early, "substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Johns Hopkins Bloomberg School of Public Health's Arturo Casadevall told The Washington Post that "the fact that the vaccine elicited neutralizing antibody amounts comparable or higher to those found in convalescent sera [plasma] is very encouraging," although the Post noted that this "represents only a first step in a long process to bring a vaccine to market." But Moderna chief executive Stephane Bancel told the Post that "we are very, very happy," noting "the vaccine was generally safe."
Moderna is moving into phase two of its clinical trials, having received approval from the Food and Drug Administration, and it says the third phase is expected to begin in the summer. Zaks told The New York Times that if all goes well, doses of a vaccine could potentially be available by the end of this year or early next year, and in terms of how many would be ready, he said "we're doing our best to make it as many millions as possible."
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Brendan worked as a culture writer at The Week from 2018 to 2023, covering the entertainment industry, including film reviews, television recaps, awards season, the box office, major movie franchises and Hollywood gossip. He has written about film and television for outlets including Bloody Disgusting, Showbiz Cheat Sheet, Heavy and The Celebrity Cafe.
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia
-
Measles outbreak spreads, as does RFK Jr.'s influence
Speed Read The outbreak centered in Texas has grown to at least three states and Health Secretary Robert F. Kennedy Jr. is promoting unproven treatments